Literature DB >> 29580170

Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats.

Kuo Zhang1,2, Yi-Da Tang1, Youhua Zhang2, Kaie Ojamaa2, Ying Li2, Amandeep Singh Saini2, Maria Alicia Carrillo-Sepulveda2, Viswanathan Rajagopalan3, A Martin Gerdes2.   

Abstract

BACKGROUND: Beta blockers are standard therapy for myocardial infarction (MI). Preclinical studies have shown efficacy and safety of thyroid hormone (TH) treatment of cardiovascular disorders. Since THs interact with the sympathoadrenergic system, this study aimed to compare triiodothyronine (T3) and metoprolol (Met) in the treatment of rats with MI on pathophysiology and TH-adrenergic signaling.
METHODS: Female Sprague-Dawley rats aged 12 weeks underwent left anterior descending coronary artery ligation (MI) or sham surgeries. T3 (5 μg/kg/day) or Met (100 mg/kg/day) was given in drinking water immediately after surgery for eight weeks. At the terminal of the experiments, the rats were subjected to morphological, functional, and molecular examination.
RESULTS: T3 and Met significantly enhanced left ventricular contractility (left ventricular fractional shortening 21.37 ± 2.58% and 21.14 ± 3.71%, respectively) compared to untreated MI (17.88 ± 1.23%), and decreased the incidence of inducible atrial tachyarrhythmia by 87.5% and 62.5%, respectively. Although both treatments showed efficacy, T3 but not Met showed statistically significant improvements compared to MI in arrhythmia duration, left atrial diameter (T3 vs. MI 4.33 ± 0.63 vs. 5.65 ± 1.32 mm; p < 0.05), fibrosis (6.1 ± 0.6%, 6.6 ± 0.6% vs. 8.2 ± 0.7%, T3, Met vs. MI, respectively), and aortic vasorelaxation responsiveness to acetylcholine (pD2 6.97 ± 0.22, 6.83 ± 0.21 vs. 6.66 ± 0.22, T3, Met vs. MI, respectively). Quantitative polymerase chain reaction showed that T3 and Met attenuated expression of genes associated with inflammation and oxidative stress and restored expression of ion channels and contractile proteins.
CONCLUSION: These results support comparable efficacy of T3 and Met treatments, suggesting that T3 may provide a therapeutic alternative to standard β-receptor blockade, especially for patients intolerant to treatment with β-blockers after MI.

Entities:  

Keywords:  heart function; metoprolol; myocardial infarction; triiodothyronine

Mesh:

Substances:

Year:  2018        PMID: 29580170      PMCID: PMC5994663          DOI: 10.1089/thy.2017.0544

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  49 in total

Review 1.  Thyroid hormone and the cardiovascular system.

Authors:  I Klein; K Ojamaa
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

2.  Subclinical thyroid dysfunction as a risk factor for cardiovascular disease.

Authors:  John P Walsh; Alexandra P Bremner; Max K Bulsara; Peter O'Leary; Peter J Leedman; Peter Feddema; Valdo Michelangeli
Journal:  Arch Intern Med       Date:  2005-11-28

3.  Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.

Authors:  David J Stott; Nicolas Rodondi; Patricia M Kearney; Ian Ford; Rudi G J Westendorp; Simon P Mooijaart; Naveed Sattar; Carole E Aubert; Drahomir Aujesky; Douglas C Bauer; Christine Baumgartner; Manuel R Blum; John P Browne; Stephen Byrne; Tinh-Hai Collet; Olaf M Dekkers; Wendy P J den Elzen; Robert S Du Puy; Graham Ellis; Martin Feller; Carmen Floriani; Kirsty Hendry; Caroline Hurley; J Wouter Jukema; Sharon Kean; Maria Kelly; Danielle Krebs; Peter Langhorne; Gemma McCarthy; Vera McCarthy; Alex McConnachie; Mairi McDade; Martina Messow; Annemarie O'Flynn; David O'Riordan; Rosalinde K E Poortvliet; Terence J Quinn; Audrey Russell; Carol Sinnott; Jan W A Smit; H Anette Van Dorland; Kieran A Walsh; Elaine K Walsh; Torquil Watt; Robbie Wilson; Jacobijn Gussekloo
Journal:  N Engl J Med       Date:  2017-04-03       Impact factor: 91.245

4.  In vivo selective expression of thyroid hormone receptor α1 in endothelial cells attenuates myocardial injury in experimental myocardial infarction in mice.

Authors:  Jorge Suarez; Hong Wang; Brian T Scott; Haiyun Ling; Ayako Makino; Eric Swanson; Joan Heller Brown; Jorge A Suarez; Shera Feinstein; Julieta Diaz-Juarez; Wolfgang H Dillmann
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-05-21       Impact factor: 3.619

Review 5.  Thyroid Hormone and Cardioprotection.

Authors:  Anthony Martin Gerdes; Kaie Ojamaa
Journal:  Compr Physiol       Date:  2016-06-13       Impact factor: 9.090

Review 6.  Thyroid-adrenergic interactions: physiological and clinical implications.

Authors:  J Enrique Silva; Suzy D C Bianco
Journal:  Thyroid       Date:  2008-02       Impact factor: 6.568

7.  Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"?

Authors:  C Pantos; C Xinaris; I Mourouzis; P Perimenis; E Politi; D Spanou; D V Cokkinos
Journal:  J Physiol Pharmacol       Date:  2008-06       Impact factor: 3.011

8.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.

Authors:  W N Leimbach; B G Wallin; R G Victor; P E Aylward; G Sundlöf; A L Mark
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

9.  Thyroid hormone replacement therapy attenuates atrial remodeling and reduces atrial fibrillation inducibility in a rat myocardial infarction-heart failure model.

Authors:  Youhua Zhang; Eduard I Dedkov; Bianca Lee; Ying Li; Khusbu Pun; A Martin Gerdes
Journal:  J Card Fail       Date:  2014-11-25       Impact factor: 5.712

10.  All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study.

Authors:  Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi
Journal:  Eur Heart J       Date:  2013-01-14       Impact factor: 29.983

View more
  7 in total

Review 1.  The impact of thyroid hormone dysfunction on ischemic heart disease.

Authors:  Madalena von Hafe; João Sergio Neves; Catarina Vale; Marta Borges-Canha; Adelino Leite-Moreira
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

2.  Management of Hypothyroidism in Patients with Acute Myocardial Infarction.

Authors:  Danielle Eagan; Gabriela Spencer-Bonilla; Spyridoula Maraka; Monica Aggarwal; Naykky Singh Ospina
Journal:  Medicina (Kaunas)       Date:  2020-04-28       Impact factor: 2.430

3.  Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment.

Authors:  Shimin An; Nimra Gilani; Yuan Huang; Adam Muncan; Youhua Zhang; Yi-Da Tang; A Martin Gerdes; Kaie Ojamaa
Journal:  Mol Med       Date:  2019-12-06       Impact factor: 6.354

4.  Triiodothyronine (T3), inflammation and mortality risk in patients with acute myocardial infarction.

Authors:  Salman Razvi; Avais Jabbar; Arjola Bano; Lorna Ingoe; Peter Carey; Shahid Junejo; Honey Thomas; Caroline Addison; David Austin; John P Greenwood; Azfar G Zaman
Journal:  Eur Thyroid J       Date:  2022-02-09

5.  FT3/FT4 ratio is correlated with all-cause mortality, cardiovascular mortality, and cardiovascular disease risk: NHANES 2007-2012.

Authors:  Xueyan Lang; Yilan Li; Dandan Zhang; Yuheng Zhang; Nilian Wu; Yao Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

6.  Novel beta-blocker pretreatment prevents alcohol-induced atrial fibrillation in a rat model.

Authors:  Hebah Hassan; Lisa V Greco; Daniel I Meshoyrer; Ying Li; Youhua Zhang; Todd J Cohen
Journal:  Heart Rhythm O2       Date:  2020-06-15

7.  BNP as a New Biomarker of Cardiac Thyroid Hormone Function.

Authors:  Kaihao Wang; Kaie Ojamaa; Abigail Samuels; Nimra Gilani; Kuo Zhang; Shimin An; Youhua Zhang; Yi-Da Tang; Bardia Askari; Anthony Martin Gerdes
Journal:  Front Physiol       Date:  2020-07-09       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.